Commercializing PEG-20k
Perfusion Medical is commercializing PEG-20k, a breakthrough IV solution for restoration of tissue perfusion invented at the Virginia Commonwealth University (VCU) School of Medicine. PEG-20k shows potential to be a disruptive solution for addressing severe blood loss (hemorrhagic shock) and related medical conditions.
Learn More
How it works
The major mechanism of action of PEG-20k IV solution in treating severe hypovolemic shock is to increase tissue perfusion to facilitate rapid transfer of oxygen into oxygen starved tissues and organs. This is accomplished by reversing the metabolic cell and tissue swelling that occurs during shock, which causes no reflow by capillary compression.
Perfusion Medical is commercializing a critical new life science technology
See our Technology and Pipeline page to learn more about how PEG-20k works and how it can potentially help patients
See our Press page to see a list of some of the impressive scientific publications about PEG-20k
Read our blogs to learn more about the Perfusion Medical team and where we are in the development, regulatory and investment process
Military Usage
The development of PEG-20k at VCU was funded with more than $10 million from the US Army. PEG-20k has tremendous potential to help war fighters and civilians
